智通财经APP讯，通化东宝(600867.SH)公告，公司全资子公司东宝紫星(杭州)生物医药有限公司(简称“东宝紫星”)完成了一项关键Ib期临床试验(“在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床研究”)并获得临床试验总结报告，研究结果显示达到主要终点目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.